OverviewChartProfileKey statisticsFinancialsNews
Derivatives
TraderScreen

SANOFI/  FR0000120578  /

Euronext Milan
2024-10-04  12:54:44 PM Chg. +0.90 Volume Bid4:34:31 PM Ask4:34:31 PM Market Capitalization Dividend Y. P/E Ratio
100.94EUR +0.90% 224
Turnover: 22,640.42		 101.62Bid Size: 260 101.72Ask Size: 260 127.94 bill.EUR 3.68% 23.68
GlobeNewswire 09-02 Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to ...
GlobeNewswire 08-26 Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...
GlobeNewswire 08-14 Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
GlobeNewswire 08-13 Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 08-12 MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter ...
GlobeNewswire 08-12 MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi
GlobeNewswire 08-08 Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free sur...
GlobeNewswire 08-06 Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D ...
GlobeNewswire 08-05 Fierce Biotech Names Recludix Pharma a “Fierce 15” Biotech Company of 2024
GlobeNewswire 08-02 Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel
GlobeNewswire 08-01 Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
GlobeNewswire 08-01 Regeneron Reports Second Quarter 2024 Financial and Operating Results
GlobeNewswire 07-31 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2...
GlobeNewswire 07-25 Press Release: Online availability of Sanofi’s half-year financial report for 2024
TeleTrader 07-25 Europe lower premarket as earnings pour in
TeleTrader 07-25 Sanofi net sales up 7.8% to €10.7B in Q2
GlobeNewswire 07-25 Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
GlobeNewswire 07-24 US Hematologists Express High Unmet Need in Treatments for Warm Autoimmune Hemolytic Anemia and Cold...
GlobeNewswire 07-18 Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, Accord...
GlobeNewswire 07-17 Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transfor...
GlobeNewswire 07-12 FluGen’s Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults Shows ...
GlobeNewswire 07-11 Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Upd...
GlobeNewswire 07-08 Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review ...
GlobeNewswire 07-03 Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients...
GlobeNewswire 07-03 Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD